ArticleFrontiers in oncology2026
Case Report: Hybrid low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma of the retroperitoneum.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retroperitoneal Sarcomas are rare malignancies that comprise 1%-2% of all malignant tumors. Among them, Low-Grade Fibromyxoid Sarcoma (LGFMS) and Sclerosing Epithelioid Fibrosarcoma (SEF) are ultra-rare sarcomas, especially in retroperitoneum. Hybrid LGFMS/SEF is even rarer, with limited cases reported in literature. We present the case of a 63-years old male with complaints on left hypochondrial discomfort, weight loss, and generalized weakness. Imaging revealed a large retroperitoneal mass with suspicion of local invasion. The patient underwent en-bloc surgical resection, including distal pancreatectomy, splenectomy, and left adrenalectomy. Histopathological examination confirmed a hybrid LGFMS/SEF with characteristic biphasic morphology. Hybrid LGFMS/SEF tumors exhibit features of both LGFMS and SEF sarcoma subtypes. Complete surgical resection remains the primary treatment strategy for localized disease. Because of the rarity of the disease, long-term surveillance is recommended. For advanced diseases, there are limited efficient available treatments necessitating the research of targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.